Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02796-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Takafumi Mie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: This study aimed to evaluate the efficacy of the second-line combination chemotherapy (CC) for patients with metastatic or recurrent pancreatic cancer. METHODS: We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer, who received second-line chemotherapy after disease progression on first-line modified FOLFIRINOX (mFFX) or gemcitabine with nab-paclitaxel (GnP) between January 2014 and March 2023 at our hospital. Overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) were compared between first-line mFFX and GnP. In addition, OS, PFS, and PPS for second-line treatment with CC and single-agent chemotherapy (SAC) were compared using propensity score matching (PSM). RESULTS: 457 patients (mFFX/GnP: 122/335) were included. Median OS and PPS of mFFX and GnP were 15.5 months vs. 15.0 months (p = 0.73) and 7.7 months vs. 7.2 months (p = 0.37), respectively. After PSM, median OS and median PPS were significantly longer in the CC group than in the SAC group (OS: 16.3 months vs. 12.8 months, p < 0.01; PPS: 8.0 months vs. 5.5 months, p < 0.01). There was no difference in first-line PFS between the two groups (7.1 months vs. 6.4 months, p = 0.74). Performance status at the beginning of first-line treatment, and carbohydrate antigen 19-9 level, Glasgow prognostic score at the end of first-line treatment, and second-line CC were independently associated with OS. CONCLUSION: Second-line CC achieved longer PPS and OS than SAC. To improve OS, it was important to receive second-line CC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. masato.ozaka@jfcr.or.jp.
Zitieren
APA
Mie, T., Ozaka, M., Okamoto, T., Takeda, T., Sato, Y., Hirai, T., Ishitsuka, T., Maegawa, Y., Furukawa, T., Suzuki, Y., Sasaki, T., & Sasahira, N. (2025). Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02796-0
Vancouver
Mie T, Ozaka M, Okamoto T, Takeda T, Sato Y, Hirai T, et al. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02796-0
BibTeX
@article{Mie2025,
author = {Mie, Takafumi and Ozaka, Masato and Okamoto, Takeshi and Takeda, Tsuyoshi and Sato, Yoichiro and Hirai, Tatsuki and Ishitsuka, Takahiro and Maegawa, Yuri and Furukawa, Takaaki and Suzuki, Yukari and Sasaki, Takashi and Sasahira, Naoki},
title = {Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02796-0}
}
EUVIMED